Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.

Source:http://linkedlifedata.com/resource/pubmed/id/21131556

Clin. Cancer Res. 2011 Feb 15 17 4 880-7

Download in:

View as

General Info

PMID
21131556